Ann Oncol
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Related Questions
What drives you to initiate a csDMARD early rather than relying on prolonged corticosteroids alone in a patient with ICI-induced inflammatory arthritis who has moderate disease activity with polyarticular involvement and tenosynovitis at the time of rheumatology referral?
1 Answers
Mednet Member
Rheumatology · Ohio State University
My approach differs somewhat from the traditional paradigm of early csDMARD initiation. In patients with immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA), particularly those with moderate disease activity, polyarticular involvement, and tenosynovitis, my primary goal is to avoid p...
How do you manage steroid-refractory immune checkpoint inhibitor induced pneumonitis?
4
4 AnswersMednet Member
Medical Oncology · Ohio State University Wexner Medical Center
Steroid-refractory immune checkpoint inhibitor (ICI)-induced pneumonitis is managed with high-dose steroids plus an additional immunosuppressive agent, like infliximab or intravenous immunoglobulin (IVIG) among others. I recommend early immunomodulatory escalation as multiple studies have shown that...